Analysts’ Recent Ratings Updates for Spyre Therapeutics (SYRE)

Several brokerages have updated their recommendations and price targets on shares of Spyre Therapeutics (NASDAQ: SYRE) in the last few weeks:

• 10/11/2026 – Spyre Therapeutics is now covered by UBS Group AG. They set a “buy” rating and a $120.00 price target on the stock.
• 10/11/2026 – Spyre Therapeutics was upgraded by UBS Group AG to “strong-buy”.
• 10/3/2026 – Spyre Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/1/2026 – Spyre Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $121.00 price target on the stock.
• 10/1/2026 – Spyre Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $110.00 price target on the stock.
• 9/9/2026 – Spyre Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $123.00 price target on the stock.
• 9/8/2026 – Spyre Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $121.00 price target on the stock.
• 9/1/2026 – Spyre Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by Deutsche Bank Aktiengesellschaft from $135.00 to $127.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by Wedbush from $130.00 to $123.00. They now have an “outperform” rating on the stock.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by BTIG Research from $132.00 to $121.00. They now have a “buy” rating on the stock.
• 8/16/2026 – Spyre Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In other Spyre Therapeutics news, Director Jeffrey W. Albers sold 18,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $104.55, for a total transaction of $1,881,900.00. Following the completion of the transaction, the director owned 9,360 shares in the company, valued at $978,588. The trade was a 65.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Heidy King-Jones sold 28,933 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $91.03, for a total transaction of $2,633,770.99. Following the completion of the sale, the insider directly owned 2,845 shares in the company, valued at approximately $258,980.35. This represents a 91.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 183,564 shares of company stock worth $16,903,193 over the last three months. Insiders own 15.69% of the company’s stock.

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.

Spyre’s pipeline includes programs directed at validated inflammatory pathways, including interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A).